Immuron Limited

IMC

AU000000IMC7

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 05:49:22 17/05/2024 BST			5-day change	1st Jan Change
0.09 ^AUD	-1.10%		+1.12%	+16.88%

05-03	Immuron Limited Announces Stephen Anastasiou Has Resigns as Non-Executive Director	CI
04-10	Immuron Limited Provides Sales Results for the Quarter and Year to Date Ended March 2024	CI

Immuron Limited Provides Group Earnings Guidance for the Year Ending June 30, 2020

October 28, 2019 at 04:01 am

Immuron Limited provided group earnings guidance for the year ending June 30, 2020. The group expects that net profit after tax will decrease by approximately $1,532 for the year ending June 30, 2020 as a result of adopting the new rules.

Latest news about Immuron Limited

Immuron Limited Announces Stephen Anastasiou Has Resigns as Non-Executive Director	05-02	CI
Immuron Limited Provides Sales Results for the Quarter and Year to Date Ended March 2024	04-10	CI
Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18%	04-10	MT
Sector Update: Health Care Stocks Gain Late Afternoon	03-07	MT
Sector Update: Health Care	03-07	MT
Top Midday Gainers	03-07	MT
Top Premarket Gainers	03-07	MT
Immuron Moving Anti-Diarrhea Drug to Phase Three Trials	03-07	MT
Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US	03-07	CI
Immuron Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Immuron Limited Reports Unaudited Net Sales Results for the Year to Date Ended January 2024	02-13	CI
Immuron's Travelan Immune Supplement Registers AU$2.7 Million Sales in YTD January	02-13	MT
Immuron Limited Reports Sales Results for First Half 2024	01-16	CI
Immuron Posts Record Travelan Sales in Fiscal H1	01-16	MT
Immuron Limited Clinical Trials Update	12-22	CI
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study	12-04	CI
Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences	18/10/23	CI
Immuron Limited Reports Sales Results for the First Quarter of 2024	11/10/23	CI
Immuron Reports Big Jump in Fiscal Q1 Travelan Sales	11/10/23	MT
Immuron Sees Nearly 8000% Boost in August Sales of Gastrointestinal Drug	14/09/23	MT
Immuron Limited Reports Earnings Results for the Full Year Ended June 30, 2023	29/08/23	CI
Immuron Limited Receives TGA GMP Clearance	09/08/23	CI
Immuron Secures Clearance for Packaging of Immunotherapy Product; Shares Surge 27%	09/08/23	MT
Immuron Says First Patients Enrolled in Travelan Trial	25/07/23	MT
Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study	25/07/23	CI

Chart Immuron Limited

Duration

Period

More charts

Company Profile

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects in Australia, Israel and the United States. The Company's flagship commercial products consist of Travelan and Protectyn. Travelan is an over the counter orally administered passive immunotherapeutic product indicated to reduce the risk of travelers' diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. The Company has four clinical programs -Travelan (IMM-124E), CampETEC, IMM-529 and Travelan (consumer product).

Sector

Pharmaceuticals

Calendar

29/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
IMMURON LIMITED	+16.88%	13.72M
CSL LIMITED	-2.32%	90.45B
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	41.45B
BIOGEN INC.	-10.90%	33.57B
UCB	+58.05%	25.73B
BIOMARIN PHARMACEUTICAL INC.	-19.56%	14.73B
INCYTE CORPORATION	-9.06%	12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.79B